Cargando…

Supply chain management in the drug industry : delivering patient value for pharmaceuticals and biologics /

"This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Rees, Hedley
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Hoboken, N.J. : Wiley, ©2011.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 EBOOKCENTRAL_ocn716206093
003 OCoLC
005 20240329122006.0
006 m o d
007 cr cn|||||||||
008 110428s2011 njua ob 001 0 eng d
010 |z  2010023288 
040 |a UIU  |b eng  |e pn  |c UIU  |d DG1  |d E7B  |d CDX  |d OCLCQ  |d OCLCO  |d DEBSZ  |d OCLCQ  |d OCLCA  |d OCLCQ  |d CHVBK  |d NLGGC  |d NLE  |d MERUC  |d EBLCP  |d YDXCP  |d UBY  |d MHW  |d IDEBK  |d N$T  |d DEBBG  |d OCLCQ  |d COO  |d AZK  |d YDX  |d COCUF  |d MOR  |d PIFAG  |d ZCU  |d OCLCQ  |d U3W  |d STF  |d WRM  |d OCLCA  |d ICG  |d INT  |d VT2  |d OCLCQ  |d WYU  |d OCLCA  |d TKN  |d OCLCQ  |d OCLCO  |d DKC  |d AU@  |d OCLCO  |d OCLCQ  |d UX1  |d OL$  |d OCLCQ  |d OCLCA  |d VLY  |d UKAHL  |d OCLCO  |d OCLCQ  |d OCLCL 
016 7 |a 101532762  |2 DNLM 
019 |a 705538737  |a 708567881  |a 711782113  |a 741259073  |a 816649018  |a 860514202  |a 961551852  |a 962621107  |a 1055365542  |a 1064134456  |a 1081222071  |a 1162583436  |a 1290080175 
020 |a 9780470920817  |q (electronic bk.) 
020 |a 0470920815  |q (electronic bk.) 
020 |a 0470555173 
020 |a 9780470555170 
020 |a 9780470920534  |q (electronic bk.) 
020 |a 047092053X  |q (electronic bk.) 
020 |z 9780470555170  |q (cloth) 
020 |z 1283025442 
020 |z 9781283025447 
020 |a 0470922842 
020 |a 9780470922842 
020 |a 9786613025449 
020 |a 6613025445 
029 1 |a AU@  |b 000048807439 
029 1 |a AU@  |b 000049641631 
029 1 |a AU@  |b 000053277932 
029 1 |a CHBIS  |b 007307087 
029 1 |a DEBBG  |b BV041049292 
029 1 |a DEBBG  |b BV041910058 
029 1 |a DEBBG  |b BV044151090 
029 1 |a DEBSZ  |b 372804578 
029 1 |a DEBSZ  |b 430946392 
029 1 |a DEBSZ  |b 449225003 
029 1 |a HEBIS  |b 299818888 
029 1 |a NZ1  |b 14255930 
035 |a (OCoLC)716206093  |z (OCoLC)705538737  |z (OCoLC)708567881  |z (OCoLC)711782113  |z (OCoLC)741259073  |z (OCoLC)816649018  |z (OCoLC)860514202  |z (OCoLC)961551852  |z (OCoLC)962621107  |z (OCoLC)1055365542  |z (OCoLC)1064134456  |z (OCoLC)1081222071  |z (OCoLC)1162583436  |z (OCoLC)1290080175 
037 |a 10.1002/9780470920817  |b Wiley InterScience  |n http://www3.interscience.wiley.com 
050 4 |a HD9665.5  |b .R44 2011 
060 4 |a 2011 D-721 
060 4 |a QV 736  |b R328s 2011 
072 7 |a MMG  |2 bicssc 
072 7 |a MED  |x 023000  |2 bisacsh 
072 7 |a MED  |x 058170  |2 bisacsh 
072 7 |a MED  |x 071000  |2 bisacsh 
072 7 |a MED  |x 072000  |2 bisacsh 
082 0 4 |a 615.1068/5  |2 22 
049 |a UAMI 
100 1 |a Rees, Hedley. 
245 1 0 |a Supply chain management in the drug industry :  |b delivering patient value for pharmaceuticals and biologics /  |c Hedley Rees. 
260 |a Hoboken, N.J. :  |b Wiley,  |c ©2011. 
300 |a 1 online resource (xxiii, 432 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
505 0 |a Frontmatter -- Surveying and Mapping the Territory. Setting a Transformational Agenda -- Plotting a Course to Patient Value -- Pharmaceutical Drug Development -- End-To-End Pharmaceutical Supply Chains -- Why Pharma Supply Chains don't Perform -- Building a knowledge Foundation in SCM. Supply Chain Management as a Competitive Weapon -- Supply Chain Management Holistic -- Production and Inventory Control -- Strategic Procurement -- Transportation, Storage, and Distribution -- Information Systems and Information Technology -- Improvement -- Bringing the Holistic Together -- Planning and Executing Supply Chain Change. Improvement in Pharmaceuticals -- Exemplar Thinking in Organizational Improvement -- Building a Foundation for Sustainable Change -- A Cure for the Pharmaceutical Supply Chain -- End Notes -- Index. 
504 |a Includes bibliographical references and index. 
505 8 |a Machine generated contents note: PART I: SURVEYING AND MAPPING THE TERRITORY. -- CHAPTER 1 SETTING A TRANSFORMATIONAL AGENDA. -- 1.1 Aims and aspirations of the book. -- 1.2 Book Format. -- 1.3 Intended readership. -- 1.4 A book about two worlds in contrast. -- 1.5 The pharmaceutical lottery. -- 1.6 Supply Chain Management (SCM) in context. -- 1.7 The History of Supply and Value Generation. -- 1.8 The Development of Processes to Manage the Supply Chain. -- 1.9 Life in SCM. -- 1.10 Moving forward. -- CHAPTER 2 PLOTTING A COURSE TO PATIENT VALUE. -- 2.1 Why focus on Patient Value? -- 2.2 Where does the patient currently fit? -- 2.3 Why is it necessary to plot a course? -- 2.4 Understanding how the course is presently set. -- 2.5 Capturing value for patients. -- CHAPTER 3 PHARMACEUTICAL DRUG DEVELOPMENT. -- 3.1 Drug development's role in the supply chain. -- 3.2 Introduction to drug development. -- 3.3 The Medicinal Product. -- 3.4 Clinical Trials. -- 3.5 Related Development Programmes. -- 3.6 Managing Clinical Programs. -- 3.7 Regulatory Affairs and Authorities. -- 3.8 Supply Chain Management in Development Programmes. -- 3.9 Manufacture and Supply of Commercial Product. -- 3.10 Supply Chain Management for Commercial Product. -- CHAPTER 4 END-TO-END PHARMACEUTICAL SUPPLY CHAINS. -- 4.1 Where does responsibility for the supply chain lay? -- 4.2 Sponsor companies, license holders and their supply chains. -- 4.3 Supply chains for small molecule products. -- 4.4 Starting at the final destination. -- 4.5 How do drugs enter the body? -- 4.6 Design of drug delivery systems. -- 4.7 What does this mean for the supply chain? -- 4.8 Key aspects of GMP/GDP in relation to SCM. -- 4.9 An overview of the stages on route to patient delivery. -- 4.10 Manufacture and supply of biological entities. -- CHAPTER 5: WHY PHARMA SUPPLY CHAINS DON'T PERFORM. -- 5.1 Supply chain underperformance. -- 5.2 Is there a case to answer? -- 5.3 Birth to infancy -- the supply chain critical stage. -- 5.4 Commercial supply under the patent protection umbrella. -- 5.4.1 Limited competitive alternatives. -- 5.4.2 Fragmentation. -- 5.4.3 Supplier power. -- 5.4.4 The position of those buying pharmaceutical products. -- 5.5 What does this mean for the pharmaceutical supply chain? 
505 8 |a PART II: BUILDING A KNOWLEDGE FOUNDATION IN SCM. -- CHAPTER 6 SUPPLY CHAIN MANAGEMENT AS A COMPETETIVE WEAPON. -- 6.1 Competition and business strategy. -- 6.2 The marketing mix. -- 6.3 Porter's Five Forces. -- 6.4 Porter's Generic Competitive Strategies. -- 6.5 Porters Value Chain. -- 6.6 Competitive strategy and customers. -- 6.7 The Japanese Experience. -- 6.8 Total Quality Management. -- 6.9 Lean Thinking. -- 6.10 Focusing on value for money. -- 6.11 SCM processes in competitive strategy. -- 6.12 SCM in biotech/virtual companies. -- 6.13 Competition in pharmaceuticals. -- CHAPTER 7 SUPPLY CHAIN MANAGEMENT (SCM) HOLISTIC. -- 7.1 The relevance of SCM to Pharmaceuticals. -- 7.2 Production systems and the holistic of SCM. -- 7.3 The Core of SCM. -- 7.4 First principle of SCM. -- 7.5 Supply chains as a series of interconnected systems. -- 7.6 Processes to manage the supply chain. -- 7.7 A word about processes. -- 7.8 How the SCM processes should mesh together. -- 7.9 Production & Inventory Control (P & IC). -- 7.10 Strategic Procurement. -- 7.11 Transportation, storage and distribution. -- 7.12 Information Systems and Technology (IS/IT). -- 7.13 Improvement. -- CHAPTER 8 PRODUCTION & INVENTORY CONTROL (P & IC). -- 8.1 Core mission. -- 8.2 First principles of production and inventory control (P & I C). -- 8.3 The Wholesome Trinity (TWT) in P & IC. -- 8.4 The Wholesome Trinity (TWT) and customer expectations. -- 8.5 Leveraging 'The Wholesome Trinity' (TWT). -- 8.6 The impact of variety on supply chains. -- 8.7 Designing appropriate production systems. -- CHAPTER 9 STRATEGIC PROCUREMENT. -- 9.1 Core mission. -- 9.2 The Purchasing Portfolio. -- 9.3 The Process of Procurement. -- 9.4 Strategic sourcing and planning. -- 9.5 Outsourcing. -- 9.6 Basic principles in contracting for supply. -- 9.7 Finally, a typical organisational tension over procurement. -- CHAPTER 10 TRANSPORTATION, STORAGE AND DISTRIBUTION. -- 10.1 Defining the core mission. -- 10.2 International trade and commerce. -- 10.3 The World Trade Organization (WTO). -- 10.4 Intermediary arrangements. -- 10.5 Terms of Trade -- Incoterms 2000. -- 10.6 Ownership of goods (Title). -- 10.7 Third Party Logistics (3PL) Providers. -- 10.8 Customs. -- 10.9 Shipping regulations relating to materials. -- 10.10 A finishing note. -- CHAPTER 11 INFORMATION SYSTEMS (IS) and INFORMATION TECHNOLOGY (IT). -- 11.1 Overview. -- 11.2 A brief (layman's -- and very brief!) history of computer systems development. -- 11.3 IS/IT and Business Process Management (BPM) -- Dee Carrie. -- 11.4 IS/IT and Supply Chain Management. -- 11.5 IS/IT and patient safety -- Adrian Hampshire. -- 11.6 IS/IT and the regulations. -- 11.7 IS/IT and SOPs. -- CHAPTER 12 IMPROVEMENT. -- 12.1 Why improve? -- 12.2 Improvement and Production Systems. -- 12.3 The improvement journey. -- CHAPTER 13 BRINGING THE HOLISTIC TOGETHER. -- 13.1 Setting the scene. -- 13.2 The process explained. -- 13.3 Developing an action agenda. -- 13.4 An illustrative case study. 
505 8 |a PART III: PLANNING AND EXECUTING SUPPLY CHAIN CHANGE. -- CHAPTER 14 IMPROVEMENT IN PHARMACEUTICALS. -- 14.1 Where are we now? -- 14.2 Subsequent developments since inception. -- 14.3 A Blueprint for Quality by Design (QbD). -- CHAPTER 15 EXEMPLAR THINKING IN ORGANISATIONAL IMPROVEMENT. -- 15.1 Where are we now? -- 15.2 What is meant by 'Exemplar'? -- 15.3 A dialogue on exemplar improvement. -- CHAPTER 16 BUILDING A FOUNDATION FOR SUSTAINABLE CHANGE. -- 16.1 Focus on the individual. -- 16.2 Individuals as leaders. -- 16.3 Individuals as motivators and the motivated. -- 16.4 Individuals as group members. -- 16.5 Individuals as participants in cultural change. -- 16.6 CASE STUDY MILES LTD., BRIDGEND, GLAMORGAN. -- CHAPTER 17 A CURE FOR THE PHARMACETICAL SUPPLY CHAIN. -- 17.1 What is the disease state? -- 17.2 What is the label claim for the Medicine? -- 17.3 What will life hold without the medicine? -- 17.4 What is this 'better way' to develop drugs? -- 17.5 Full scale production of drugs. -- 17.6 What are the barriers to change? -- 17.7 What are the potential benefits of change? -- 17.8 Defining the art of the possible. -- 17.9 Concluding message. 
520 |a "This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials"--Provided by publisher. 
588 0 |a Print version record. 
546 |a English. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Pharmaceutical industry  |x Materials management. 
650 2 |a Drug Industry  |x organization & administration 
650 6 |a Industrie pharmaceutique  |x Gestion de l'approvisionnement. 
650 7 |a MEDICAL  |x Drug Guides.  |2 bisacsh 
650 7 |a MEDICAL  |x Nursing  |x Pharmacology.  |2 bisacsh 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a MEDICAL  |x Pharmacy.  |2 bisacsh 
758 |i has work:  |a Supply Chain Management in the Drug Industry [electronic resource] (Text)  |1 https://id.oclc.org/worldcat/entity/E39PD3CX43wc4crm8wByjdCGYd  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |a Rees, Hedley.  |t Supply chain management in the drug industry.  |d Hoboken, N.J. : Wiley, ©2011  |z 9780470555170  |w (DLC) 2010023288  |w (OCoLC)642278451 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=661675  |z Texto completo 
938 |a Askews and Holts Library Services  |b ASKH  |n AH13355496 
938 |a Coutts Information Services  |b COUT  |n 17556559 
938 |a EBL - Ebook Library  |b EBLB  |n EBL661675 
938 |a ebrary  |b EBRY  |n ebr10446690 
938 |a EBSCOhost  |b EBSC  |n 518224 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n 302544 
938 |a YBP Library Services  |b YANK  |n 3537798 
938 |a YBP Library Services  |b YANK  |n 3350550 
938 |a YBP Library Services  |b YANK  |n 12667906 
994 |a 92  |b IZTAP